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Abstract 
Aim: Hepatocellular carcinoma (HCC) develops with high incidence in patients with chronic liver 
disease (CLD), and particularly in those with cirrhosis. Currently, diagnosis and surveillance are 
mainly based on imaging-methods. The aim of this study was to evaluate the diagnostic accuracy of 
highly sensitive measurement of alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive 
fraction of AFP (AFP-L3) and des-gamma-carboxy-prothrombin (DCP) alone and in combination, 
for early HCC detection. In addition, a recently proposed statistical model, including these three 
biomarkers plus gender and age, the GALAD model  was applied. 
Methods: In a total of 98 patients [44 CLD patients without HCC (23M, 21F; mean age 53.2±13.4 
years) and 54 patients with HCC (45M, 9F; 69.5±9.8 years)] AFP, AFP-L3 and DCP levels were 
determined using a highly sensitive assay on µTASWako i30 immuno-analyzer. Areas under the 
curve (AUC) were calculated and compared to assess diagnostic performance of the HCC 
biomarkers and of the GALAD model. 
Results: AFP, AFP-L3 and DCP were significantly elevated in HCC compared to CLD patients 
(p<0.0001). AUC values were 0.891, 0.867 and 0.870 respectively. The combination of the 3 
biomarkers resulted in AUC=0.947 (Se=94.3%; 87.6% of patients correctly classified), whereas the 
GALAD model showed a AUC=0.976 (Se=96.3, specificity=84.1%, positive predictive 
value=88.1%; negative predictive value=94.9%; 89.8% of patients correctly classified). 
Conclusions: These data confirm the elevated accuracy of highly sensitive methods for AFP, AFP-
L3 and DCP quantitation. Moreover, the combination of these serological biomarkers and 
application of the GALAD model could improve HCC early detection and current surveillance 
efficiency. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is one of the most frequent malignancy and the third cause of 
cancer-related death in the world,
1
 representing a major global health problem. The principal risk 
factor for HCC development is cirrhosis, especially in patients with an underlying hepatitis B and C 
infection.
2
 According to the European Association for the Study of the Liver (EASL) and the 
American Association for the Study of Liver Diseases (AASLD) clinical guidelines for HCC 
management, surveillance should be performed every 6 months in all at-risk patients using 
abdominal ultrasound (US), and diagnosis should be based on imaging methods, such as computed 
tomography (CT) and magnetic resonance imaging (MRI), and/or biopsy.
3,4
 Besides imaging 
methods, the Japan Society of Hepatology (JSH) guidelines suggest the use of tumor markers such 
as alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-
gamma-carboxy-prothrombin (DCP) for surveillance programs and for early HCC detection.
5,6
 
Moreover, in a recent study, Johnson PJ et al developed a model (GALAD)  that is based on the 
objective measures of Gender, Age and three serological biomarkers, AFP, AFP-L3 and DCP for 
the detection of HCC, showing excellent diagnostic accuracy, even in patients with early disease as 
classified by Barcelona Liver Cancer Clinics (BCLC) staging system.
7
  
Since recent technical improvements in the analytical methods of measuring AFP, AFP-L3 and 
DCP employing an advanced microfluidics-based separation technology have been developed,
8
 the 
aim of the present study was to evaluate the diagnostic accuracy of AFP, AFP-L3 and DCP alone or 
in combination and to test GALAD model performance for HCC detection in a cohort of Italian 
patients. 
 
METHODS 
Patients 
This single-center cross-sectional study included 98 prospectively enrolled patients (68M, 30F; 
mean age 62.2 ± 14.1 years) with chronic liver disease (CLD) that underwent US screening for 
hepatic nodular lesion. Final diagnosis of HCC was established by 4-phase multidetector CT scan or 
dynamic contrast-enhanced MRI showing arterial hypervascularity and washout in the venous/late 
phase.
3
 The degree of liver disease was classified according to clinical, serological and histological 
criteria where appropriate. Liver cirrhosis was diagnosed by liver biopsy or by laboratory data and 
imaging findings (US and transient elastography).
9,10
 All patients gave their written informed 
consent prior to recruitment. The study protocol was conformed to the principles of the Declaration 
of Helsinky and it was approved by the Institutional Ethics Committee. 
 
Measurements of serological biomarkers 
Blood samples were collected from each participant at the time of the scheduled outpatient visit. 
Sera were stored at -80°C and subsequently analyzed for the concentration of AFP, AFP-L3 and 
DCP using an automated immunoassay system assay on the µTASWako i30 immuno-analyzer 
(Wako Chemicals GmbH, Neuss, Germany).
11,12
 Analytical assay sensitivities are 0.3 ng/mL for 
AFP and 0.1 ng/mL for DCP. AFP-L3 is reportable as ratio to total AFP if both AFP-L1 and AFP-
L3 are ≥ 0.3 ng/ml. All measurements were carried out in the same sample and were performed in 
an outside laboratory blinded to diagnosis and details of the patients' clinical histories.  
 
Statistical analysis 
AFP, AFP-L3 and DCP values are expressed in medians and ranges. Kruskal-Wallis test was used 
to evaluate differences in HCC biomarkers levels among groups, while Fisher's exact test was 
performed to analyze categorical data. To evaluate diagnostic performance of AFP, AFP-L3 and 
DCP alone or in combination, area under the curve (AUC), sensitivity (Se), specificity (Sp), 
positive predictive value (PPV) and negative predictive value (NPV) were assessed by using 
receiver operating characteristic (ROC) curves analysis. A logistic regression analysis was 
performed to evaluate the association of each biomarker with demographical and clinical factors. A 
p-value <0.05 was considered statistically significant. All statistical analyses were performed using 
MedCalc software, version 9.2.1.0. 
 
RESULTS 
Patient’s demographic and clinical characteristics are reported in Table 1. The population studied 
comprised of 44 CLD patients without HCC (23M, 21F; mean age 53.2 ± 13.4 years) and 54 
patients with diagnosis of HCC (45M, 9F; 69.5 ± 9.8 years). The etiology of liver disease among 
HCC patients was mainly viral (80%) followed by alcoholic and nonalcoholic steato-hepatitis, 
whereas etiology of liver disease in CLD group was exclusively viral. Almost all patients in the 
HCC group had cirrhosis (96%), while only the 31.8% of CLD patients showed histological or 
clinical signs of cirrhosis. The majority of HCC patients (85.2%) were diagnosed early stage (0 and 
A) according to BCLC staging system. 
Median levels for AFP, AFP-L3 and DCP were significantly different between patients with and 
without HCC (p<0.0001) (Figure 1) (Table 2). To evaluate whether different demographic and 
clinical factors could affect AFP, AFP-L3 and DCP performance, a logistic regression analysis was 
performed. Gender, age and underlying etiology of liver disease had no influence on the levels of 
the measured biomarkers (p>0.05). Regarding severity of liver disease, only a weak association was 
found between the presence of cirrhosis and AFP-L3 values (OR=1.1753, 95%CI 1.0121-1.3648; 
p=0.034). Conversely, either DCP and AFP-L3 resulted associated with HCC diagnosis 
(OR=9.1218, 95%CI 1.8085-46.0087,  p=0.007 and OR=1.2283, 95%CI 1.0281-1.4675, p=0.023; 
respectively), whereas AFP showed just a trend (OR=1.1063, 95%CI 0.9972-1.2272; p=0.056).  
ROC curves were calculated to evaluate diagnostic accuracy for AFP, AFP-L3 and DCP alone or in 
combination to distinguish CLD from HCC (Figure 2). AUC values, Se, Sp, PPV, NPV and the 
corresponding cut-off are reported in Table 3. 
The GALAD model, including gender, age, AFP-L3, AFP and DCP, was tested on our data set and 
showed a high diagnostic accuracy for HCC diagnosis (Table 4). Furthermore a comparison of the 
diagnostic performance between each biomarker and the GALAD model was performed. 
Differences between AUC values and corresponding statistical significance are reported in Table 5. 
 
DISCUSSION 
In the present study AFP, AFP-L3 and DCP showed significantly different median values between 
CLD and HCC patients and a high diagnostic performance when used as single biomarker 
(AUC=0.891, AUC=0.870 and AUC=0.867, respectively), allowing patients correct classification in 
at least 80% of subjects. Moreover, the combination of the 3 biomarkers significantly improved the 
diagnostic accuracy (AUC=0.947), enhancing Se in HCC detection (Se=94.3%; 87.6% of patients 
correctly classified). 
AFP in particular, has been widely used as biomarker for HCC though several studies showed a 
lack of adequate Se and Sp for effective surveillance and diagnosis inasmuch that AASLD 
guidelines state that surveillance should rely on US examination only, whereas EASL guidelines 
adopt also AFP for surveillance purposes.
13,14
 In fact, several studies reported Sp values 
approaching 90% for all 3 biomarkers, but significant lower Se (<50%), in particular for early HCC 
detection.
15
 Ultrasound  used as surveillance test showed Se values ranging from 58% to 89%,
16,17
 
albeit being less effective for early-stage HCC detection (Se=63%).
13
 Conversely, JSH guidelines 
recommend to conduct surveillance programs using a combination of tumor biomarkers such AFP, 
AFP-L3 and DCP in addition to US for early HCC detection in patients with hepatitis B and C 
virus-related CLD. Moreover, the strategy to adopt US and AFP has been shown to be helpful and 
cost-effective particularly in patients with cirrhosis.
18,19
  
It is well known that older age and male gender are important risk factors that correlate with HCC 
development.
20
 These parameters have been included in the GALAD model developed by Johnson 
et al that showed a higher diagnostic accuracy for HCC detection than the combination of AFP, 
AFP-L3 and DCP in our cohort of patients (ΔAUC=0.029, p=0.028). Moreover, considering that the 
majority of HCC patients enrolled in our study were stage 0 (27.8%) or stage A (57.4%) according 
to BCLC staging system, the performance we observed suggests that this model could be suitable 
for early HCC detection despite a validation in a larger cohort of patients is required. 
A limitation of our study could be the difference in etiology and in cirrhosis prevalence between the 
CLD and HCC patients group. These features, together with  the high occurrence of early stage  
tumors in the HCC group and with the treatment status of  HBV- CLD  patients (all under 
nucleos(t)ide analogue treatment), could explain both the lower median values of AFP, DCP and 
AFP-L3  and the  low cut-off  found in these cohort. Even if demographic characteristics were not 
properly balanced between CLD and HCC patients, when we evaluated whether these differences 
could impact HCC biomarkers performance, we found no effect. 
In conclusion, our data gather further evidence for the use of highly sensitive methods for AFP, 
AFP-L3 and DCP quantitation for HCC detection. The combination of these biomarkers in addition 
to state-of-the-art ultrasound imaging may prove more powerful to identify patient at risk of HCC in 
surveillance protocols. 
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Table 1 Characteristics of patients with hepatocellular carcinoma and chronic liver disease 
  All patients CLD HCC 
Demographics     
 Number of patients 98 44 54 
 Age (years), mean ± SD 62.2 ± 14.1 53.2 ± 13.4 69.5 ± 9.8 
 Gender (M/F) 68/30 23/21 45/9 
Etiology     
 HCV 45 (45.9%) 9 (20.5%) 36 (66.7%) 
 HBV 36 (36.7%) 31 (70.5%) 5 (9.3%) 
 HCV + HBV 2 (2.0%) 0 2 (3.7%) 
 HBV + HDV 4 (4.1%) 4 (9.0%) 0 
 Alcohol 9 (9.2%) 0 9 (16.6%) 
 NASH 2 (2.0%) 0 2 (3.7%) 
Biochemistry     
 AST (IU/L), median (range) 38 (14-327) 24 (14-109) 64 (17-327) 
 ALT (IU/L), median (range) 36 (9-382) 26 (9-200) 48 (12-382) 
 Albumin (g/dL), median 
(range) 
4.1 (2.3-5.1) 4.4 (3.5-5.1) 3.9 (2.3-4.9) 
 PLT (10
9
/L), median (range) 129 (32-352) 175 (78-352) 106 (32-256) 
Cirrhosis  66 (67.3%) 14 (31.8%) 52 (96.3%) 
BCLC staging     
 0  / / 15 (27.8%) 
 A  / / 31 (57.4%) 
 B  / / 8 (14.8%) 
 C  / / 0 
 D / / 0 
 
ALT, alanine aminotransferase; AST. Aspartate aminotransferase; BCLC, Barcelona Liver Cancer 
Clinics; CLD, chronic liver disease; F, female; HCC, hepatocellular carcinoma; M, male; PLT, 
platelet count; SD, standard deviation.
Table 2 AFP, DPC and AFP-L3 values in hepatocellular carcinoma and chronic liver disease 
cohorts 
 CLD HCC p 
AFP (ng/mL), median (range) 2.3 (1.0 - 25) 13.4 (2.4 - 5785.0) <0.0001 
DCP (ng/mL), median (range) 0.26 (0.10 - 1.45) 1.13 (0.10 - 87.49) <0.0001 
AFP-L3 (%), median (range) 1.0 (1.0 - 15.1) 5.9 (1.0 - 81.6) <0.0001 
 
AFP, alpha-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive fraction of AFP; CLD, chronic 
liver disease; DCP, des-gamma-carboxy-prothrombin; HCC, hepatocellular carcinoma.
Table 3 AUC values, Se, Sp, PPV and NPV of AFP, DCP and AFP-L3 alone or in 
combination. 
 AUC Cut-off Se Sp PPV NPV Correctly classified 
AFP (ng/mL) 0.891 5.3 81.1 86.4 87.8 79.2 79.4% 
DCP (ng/mL) 0.870 0.4 77.8 90.9 91.3 76.9 79.6% 
AFP-L3 (%) 0.867 1.0 84.9 88.6 90.0 83.0 84.5% 
AFP + AFP-L3 + DCP 0.947 / 94.3 86.4 89.3 92.7 87.6% 
 
AFP, alpha-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive fraction of AFP; AUC, area 
under the curve; DCP, des-gamma-carboxy-prothrombin; NPV, negative predictive value; PPV, 
positive predictive value; Se, sensitivity; Sp, specificity. 
Table 4 AUC values, Se, Sp, PPV and NPV at different cut-off levels of GALAD model 
AUC Cut-off Se Sp PPV NPV FN FP Correctly classified 
0.976 -2.94 100 77.3 84.4 100 10 0 89.8% 
0.976 -2.59 96.3 84.1 88.1 94.9 7 3 89.8% 
0.976 0.16 57.4 100 100 65.7 0 23 76.5% 
 
AFP, alpha-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive fraction of AFP; AUC, area 
under the curve; DCP, des-gamma-carboxy-prothrombin; FN, false negative; FP, false positive; 
NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity. 
Table 5 AUC values comparison between AFP, AFP-L3, DCP and GALAD model 
 DCP AFP-L3 AFP + DCP + AFP-L3 GALAD model 
AFP 
ΔAUC=0.024 
p=0.611 
ΔAUC=0.024 
p=0.551 
ΔAUC=0.056 
p=0.063 
ΔAUC=0.085 
p=0.011 
DCP / 
ΔAUC=0.003 
p=0.996 
ΔAUC=0.080 
p=0.002 
ΔAUC=0.106 
p=0.001 
AFP-L3 / / 
ΔAUC=0.080 
p=0.022 
ΔAUC=0.109 
p=0.002 
AFP + DCP + AFP-L3 / / / 
ΔAUC=0.029 
p=0.028 
 
AFP, alpha-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive fraction of AFP; AUC, area 
under the curve; DCP, des-gamma-carboxy-prothrombin. 
Fig. 1 AFP, DCP and AFP-L3 values in hepatocellular carcinoma and chronic liver disease cohorts 
 
Fig. 2 ROC curves showing the performance of AFP, AFP-L3 and DCP alone and in combination 
 
 
 
